{
  "created_at": "Thu May 27 2:40:15 +0000 2021",
  "id_str": "1397678900738678786",
  "full_text": "A Covid-19 antibody drug from Vir and GlaxoSmithKline was authorized by the FDA, becoming the latest option for treating patients early in the course of their disease at high risk of developing serious cases https://t.co/Nnqqu7TMoZ",
  "display_text_range": [
    0,
    231
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/Nnqqu7TMoZ",
        "expanded_url": "https://on.wsj.com/3ujwOGo",
        "display_url": "on.wsj.com/3ujwOGo",
        "indices": [
          208,
          231
        ]
      }
    ]
  },
  "user": {
    "name": "The Wall Street Journal",
    "screen_name": "WSJ",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/971415515754266624/zCX0q9d5_normal.jpg"
  },
  "retweet_count": 39,
  "favorite_count": 85,
  "possibly_sensitive": false,
  "original_created_at": "Wed May 26 22:19:52 +0000 2021",
  "localize": [
    {
      "locale": "ja",
      "full_text": "Vir社とグラクソ・スミスクライン社のCovid-19抗体医薬品がFDAに認可され、重篤な症例を発症するリスクの高い疾患の早期段階の患者を治療するための最新の選択肢となった https://t.co/Nnqqu7TMoZ"
    },
    {
      "locale": "zh",
      "full_text": "Vir公司和葛兰素史克公司的一种Covid-19抗体药物获得了美国食品和药物管理局的授权，成为治疗病程早期高风险患者的最新选择https://t.co/Nnqqu7TMoZ。"
    },
    {
      "locale": "zh-Hant",
      "full_text": "Vir公司和葛蘭素史克公司的一種Covid-19抗體藥物獲得了美國食品和藥物管理局的授權，成爲治療病程早期高風險患者的最新選擇https://t.co/Nnqqu7TMoZ。"
    }
  ]
}